Guan et al. inferred that no statistical difference exists between GLP1-RA and Tirzepatide for the safety concerns while insulin caused fewer gastrointestinal events; while another meta-analysis, by Tang et al., documented an increased risk of gastrointestinal AEs with Tirzepatide mainly as add-on therapy but not in terms of pancreatitis or cholelithiasis [11-13]. The gene discussed is GLP1R; the disease is pancreatitis.